Program
bempedoic acid
Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.
Drug pageBempedoic acid: every studyMany companies study it; this page follows only the 33 they lead. All 43 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Esperion Therapeuticsits history only | 200 open or running | phase 4since Aug 27, 2023 | Dec 16, 2010 | none ahead |
| Daiichi Sankyoits history only | 61 open or running | phase 4since Apr 6, 2025 | Apr 6, 2025 | Jun 1, 2028phase 3 · NCT07474649 |
| Otsukaits history only | 30 open or running | phase 3since Jan 4, 2023 | Mar 2, 2021 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 20 open or running | phase 1since Apr 4, 2025 | Apr 4, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since May 29, 2026 | May 29, 2026 | Jun 30, 2027phase 3 · NCT07623915 |
| Gan & Lee Pharmaceuticalsits history only | 10 open or running | phase 3since Jan 13, 2025 | Jan 13, 2025 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Dec 16, 2010.
- Jun 19, 2017Phase 2 study in HypercholesterolemiaEsperion Therapeutics · NCT03193047 · 59 enrolled · United States
- Nov 6, 2017Phase 3 study in HyperlipidemiasEsperion Therapeutics · NCT03337308 · 382 enrolled · United States
- Mar 2, 2021Otsuka’s first study: phase 2 study in HypercholesterolemiaNew to OtsukaOtsuka · NCT04784442 · 188 enrolled · Japan
- Jan 4, 20232 phase 3 studies in Hyper-low-density Lipoprotein (LDL) CholesterolemiaOtsuka · NCT05687071, NCT05683340
- Jan 12, 2023Phase 2 study in HypercholesterolemiaEsperion Therapeutics · NCT05694260 · 31 enrolled · United States, Canada, Denmark and more
- Aug 27, 2023Phase 4 study in Healthy Lactating WomenEsperion Therapeutics · NCT06021951 · 16 enrolled · United States
- Jan 13, 2025Gan & Lee Pharmaceuticals’ first study: phase 3 study in HyperlipidemiasNew to Gan & Lee PharmaceuticalsGan & Lee Pharmaceuticals · NCT06780410 · 245 enrolled · China
- Apr 4, 2025Humanis Saglık Anonim Sirketi’s first study: phase 1 study in HypercholesterolemiaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06923956 · 14 enrolled · India
- Apr 6, 2025Daiichi Sankyo’s first study: phase 4 study in Hyperlipoproteinemia Type IINew to Daiichi SankyoDaiichi Sankyo · NCT06925100 · 180 enrolled · Taiwan
- Sep 5, 2025Phase 1 study in HypercholesterolemiaHumanis Saglık Anonim Sirketi · NCT07170852 · 32 enrolled · India
- Sep 11, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07182383, NCT07201545
- Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
- Mar 11, 2026Phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649 · 103 planned · Germany, Italy, Spain
- May 29, 2026CSPC Pharmaceutical Group’s first study: phase 3 study in Primary HyperlipidemiaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07623915 · 222 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Primary HyperlipidemiaCSPC Pharmaceutical Group · NCT07623915
- Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649
TargetBeta
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07623915Primary Hyperlipidemia | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2027 | 222 |
| NCT07474649Coronary Artery Disease · Germany, Italy, Spain | 3 | Recruiting | Daiichi Sankyo | Jun 1, 2028 | 103 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Jan 28, 2026 | 58 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Nov 24, 2025 | 58 |
| NCT07170852Hypercholesterolemia · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jun 16, 2025 | 32 |
| NCT06925100Hyperlipoproteinemia Type II · Taiwan | 4 | Completed | Daiichi Sankyo | Oct 15, 2025 | 180 |
| NCT06923956Hypercholesterolemia · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Dec 18, 2024 | 14 |
| NCT06780410Hyperlipidemias · China | 3 | Completed | Gan & Lee Pharmaceuticals | Aug 5, 2025 | 245 |
| NCT06021951Healthy Lactating Women · United States | 4 | Completed | Esperion Therapeutics | Feb 21, 2024 | 16 |
| NCT05694260Hypercholesterolemia · United States, Canada, Denmark and more | 2 | Completed | Esperion Therapeutics | Jun 4, 2025 | 31 |
| NCT05687071Hyper-low-density Lipoprotein (LDL) Cholesterolemia · Japan | 3 | Completed | Otsuka | Oct 5, 2024 | 130 |
| NCT05683340Hyper-low-density Lipoprotein (LDL) Cholesterolemia · Japan | 3 | Completed | Otsuka | Feb 20, 2024 | 96 |
| NCT04784442Hypercholesterolemia · Japan | 2 | Completed | Otsuka | Apr 18, 2022 | 188 |
| NCT03337308Hyperlipidemias · United States | 3 | Completed | Esperion Therapeutics | Jun 18, 2018 | 382 |
| NCT03193047Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Jan 29, 2018 | 59 |
| NCT03067441Hypercholesterolemia · United States | 3 | Completed | Esperion Therapeutics | Nov 5, 2019 | 1,462 |
| NCT03051100Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Jun 1, 2017 | 63 |
| NCT03001076Hypercholesterolemia · United States | 3 | Completed | Esperion Therapeutics | Jan 11, 2018 | 269 |
| NCT02993406Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Completed | Esperion Therapeutics | Nov 7, 2022 | 13,970 |
| NCT02991118Hypercholesterolemia · United States | 3 | Completed | Esperion Therapeutics | Aug 22, 2018 | 779 |
| NCT02988115Hypercholesterolemia · United States, Canada | 3 | Completed | Esperion Therapeutics | Mar 16, 2018 | 345 |
| NCT02666664Hypercholesterolemia · United States, Canada, Germany and more | 3 | Completed | Esperion Therapeutics | Feb 21, 2018 | 2,230 |
| NCT02659397Hyperlipidemias · United States | 2 | Completed | Esperion Therapeutics | Jul 2016 | 68 |
| NCT02178098Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | May 22, 2015 | 143 |
| NCT02072161Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Jan 2015 | 133 |
| NCT01941836Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Oct 2014 | 349 |
| NCT01779453Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | Aug 2013 | 58 |
| NCT01751984Hypercholesterolemia · United States | 2 | Completed | Esperion Therapeutics | May 1, 2013 | 56 |
| NCT01607294Hyperlipidemias · United States | 2 | Completed | Esperion Therapeutics | Oct 2012 | 60 |
| NCT01485146Safety Evaluation of Escalating Doses · United States | 1 | Completed | Esperion Therapeutics | Jan 25, 2012 | 24 |
| NCT01262638Dyslipidemias · United States | 2 | Completed | Esperion Therapeutics | Aug 23, 2011 | 177 |
How it is read
Names in the registry
- “ETC-1002”, 10 entries
- “Bempedoic acid”, 7 entries
- “180mg of ETC-1002(bempedoic acid)”, 3 entries
- “bempedoic acid”, 3 entries
- “Bempedoic Acid Tablet”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 16 studies
- Hyperlipidemias, 5 studies
- Dyslipidemias, 2 studies
- Coronary Artery Disease, 1 study
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.